Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study)
https://doi.org/10.14341/2072-0351-6058
Abstract
Aim.
To analyse factors hampering the achievement of compensation of carbohydrate metabolism in patients with type 2 diabetes mellitus treated for3 months with diabeton MB at a daily dose of 90-120 mg under real practical conditions.
Materials and methods.
This open study included 70 patients with type 2 diabetes mellitus given gliclazide MB-based hypoglycemic therapy(90-120 mg/day); their HbA1c level was measured before and 3 months after the onset of therapy.
Results.
The treatment resulted in a significant decrease of the HbA1c level especially pronounced in patients capable of following the rational therapeuticstrategy. At the closing visit, each patient was prescribed a pathogenetically sound regime of combined hypoglycemic therapy.
Conclusion.
Poor efficacy of hypoglycemic treatment in real clinical practice is attributable to frequent prescription of monotherapy, untimely onsetof insulin administration, its correction and intensification to meet changing requirements
To analyse factors hampering the achievement of compensation of carbohydrate metabolism in patients with type 2 diabetes mellitus treated for3 months with diabeton MB at a daily dose of 90-120 mg under real practical conditions.
Materials and methods.
This open study included 70 patients with type 2 diabetes mellitus given gliclazide MB-based hypoglycemic therapy(90-120 mg/day); their HbA1c level was measured before and 3 months after the onset of therapy.
Results.
The treatment resulted in a significant decrease of the HbA1c level especially pronounced in patients capable of following the rational therapeuticstrategy. At the closing visit, each patient was prescribed a pathogenetically sound regime of combined hypoglycemic therapy.
Conclusion.
Poor efficacy of hypoglycemic treatment in real clinical practice is attributable to frequent prescription of monotherapy, untimely onsetof insulin administration, its correction and intensification to meet changing requirements
About the Authors
Irina Evgen'evna Sapozhnikova
Kirov State Medical Academy, Kirov
Elena Nikolaevna Anufrieva
Kirov State Medical Academy, Kirov
Ekaterina Iosifovna Tarlovskaya
Kirov State Medical Academy, Kirov
Alexander Anatol'evich Sobolev
Kirov State Medical Academy, Kirov
References
1. Wild S., Roglic G., Green A. et al. Global prevalence of diabetes: estimated for the year 2000 and projections for 2030 // Diabetes Care. - 2004. - Vol. 27. - Р. 1047-1053.
2. Дедов И.И., Шестакова М.В. Сахарный диабет. - М.: Изд-во «Универсум Паблишинг». - 2003. - 282 с.
3. Johnstone M.T., Nesto R., Kahn R.C. et al. Diabetes Mellitus and heart disease // Joslin's Diabetes Mellitus. - Lippincott Williams & Wilkins. - 2010. - P. 975-977.
4. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group // Lancet. - 1998. - Vol. 352. - Р. 837-853.
5. Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes // N. Engl. Med. - 2003. - Vol. 348. - P. 383-393.
6. Guadelines on diabetes, prediabetes, and cardiovascular diseases: full text // Eur Heart J. - 2007. - Suppl. 9. - Р.C3-C74.
Review
For citations:
Sapozhnikova I.E., Anufrieva E.N., Tarlovskaya E.I., Sobolev A.A. Barriers for efficacious hypoglycemic therapy in clinical practice (results of the Dialogue study). Diabetes mellitus. 2010;13(4):54-56. (In Russ.) https://doi.org/10.14341/2072-0351-6058
Views:
454
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
